For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
CCTG is pleased to announce that the 2020 CCTG Phase III Team Award for Intergroup-Led trials has been awarded to the Saskatoon Cancer Centre MAC.21 trial team based on the centre's accrual metrics both overall and for this past year, local activation timelines, and compliance metrics.
The team members include: Nayyer Iqbal, Osama Ahmed, Shahid Ahmed, Tehmina Asif, Kamal Haider, Amer Sami, Mita Manna, Andrea Gallivan, Dominique Wagner, Jolene Hicks.
Two CCTG researchers were recently awarded nearly $2 million from the Canadian Cancer Society and the Conquer Cancer-Breast Cancer Research Foundation to support conduct of CCTG Investigational New Drug trials.
CCTG is pleased to announce that the 2020 CCTG Phase III Team Award for CCTG-Led trials has been awarded to the Princess Margaret Cancer Centre HN.10 trial team based on the centre's accrual metrics both overall and for this past year, local activation timelines, and compliance metrics.
CCTG is pleased to announce that the 2020 CCTG IND Team Award has been awarded to the BCCA Vancouver Centre IND.234 trial team based on the centre's accrual metrics both overall and for this past year, local activation timelines, and compliance metrics.
The team members include: Kim Chi, Manahil Sadiq, Julita Sienkiewicz, and Wendy Won.
CCTG is very pleased to announce that Dr. Dan Renouf has been awarded the CCTG Dr. Ralph Meyer Phase III Program Young Investigator Award.
This award honours young investigators who have contributed significantly on CCTG phase III projects with CCTG Disease Site Committees, Endpoint Committees, or Working Groups.
“I’m very honored to both be nominated for and to receive this award. The mentorship provided to me by many members within CCTG is very much appreciated," says Dr. Renouf.
CCTG is pleased to announce that the 2020 CCTG Phase III Team Award for Intergroup-Led trials has been awarded to the Princess Margaret Cancer Centre CE.8 trial team based on the centre's accrual metrics both overall and for this past year, local activation timelines, and compliance metrics.
CCTG is very proud to announce that Dr. Lillian Siu, Princess Margaret Cancer Centre, has been chosen as the recipient of the 2020 International Women Who Conquer Cancer Mentorship Award. Dr. Siu is the director of the Phase I Program, co-director of the Bras and Family Drug Development Program, and clinical lead for the Tumor Immunotherapy Program at Princess Margaret and is Co-Chair of CCTG's Head and Neck Site Committee. She also holds the BMO Chair in Precision Genomics.
CCTG is very pleased to announce that Dr. Sara Taylor is the 2020 recipient of the Dr. Elizabeth Eisenhauer Early Drug Development Young Investigator Award.
This award honours young investigators who have participated in the Investigational New Drug (IND) Program and have significantly contributed to IND trial conduct within their institution. Individuals are nominated by their colleagues and the IND Director/Executive Committee to determine the awardee.
